Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

J. R. Brown, W. A. Harb, B. T. Hill, J. Gabrilove, J. P. Sharman, M. T. Schreeder, P. M. Barr, J. M. Foran, T. P. Miller, J. A. Burger, K. R. Kelly, D. Mahadevan, S. Ma, Y. Li, D. W. Pierce, E. Barnett, J. Marine, M. Miranda, A. Azaryan, X. Yu, P. Nava-Parada, J. Mei, T. J. Kipps

Open source

DOI: 10.3324/haematol.2015.140806
Published: 2016-05-05
Container: Haematologica
Publisher: Ferrata Storti Foundation (Haematologica)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2015.140806,
  title = {Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia},
  author = {J. R. Brown and W. A. Harb and B. T. Hill and J. Gabrilove and J. P. Sharman and M. T. Schreeder and P. M. Barr and J. M. Foran and T. P. Miller and J. A. Burger and K. R. Kelly and D. Mahadevan and S. Ma and Y. Li and D. W. Pierce and E. Barnett and J. Marine and M. Miranda and A. Azaryan and X. Yu and P. Nava-Parada and J. Mei and T. J. Kipps},
  year = {2016},
  journal = {Haematologica},
  doi = {10.3324/haematol.2015.140806},
  url = {https://doi.org/10.3324/haematol.2015.140806}
}

RIS

TY  - JOUR
TI  - Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
AU  - J. R. Brown
AU  - W. A. Harb
AU  - B. T. Hill
AU  - J. Gabrilove
AU  - J. P. Sharman
AU  - M. T. Schreeder
AU  - P. M. Barr
AU  - J. M. Foran
AU  - T. P. Miller
AU  - J. A. Burger
AU  - K. R. Kelly
AU  - D. Mahadevan
AU  - S. Ma
AU  - Y. Li
AU  - D. W. Pierce
AU  - E. Barnett
AU  - J. Marine
AU  - M. Miranda
AU  - A. Azaryan
AU  - X. Yu
AU  - P. Nava-Parada
AU  - J. Mei
AU  - T. J. Kipps
PY  - 2016
JO  - Haematologica
DO  - 10.3324/haematol.2015.140806
UR  - https://doi.org/10.3324/haematol.2015.140806
ER  -

APA

Brown, J. R., Harb, W. A., Hill, B. T., Gabrilove, J., Sharman, J. P., Schreeder, M. T., Barr, P. M., Foran, J. M., Miller, T. P., Burger, J. A., Kelly, K. R., Mahadevan, D., Ma, S., Li, Y., Pierce, D. W., Barnett, E., Marine, J., Miranda, M., Azaryan, A., Yu, X., Nava-Parada, P., Mei, J., & Kipps, T. J. (2016). Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica. https://doi.org/10.3324/haematol.2015.140806

Source records

crossref · retrieved 2026-09-25T23:27:11.160Z